Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) ...Middle East

APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigue in the majority...

Hence then, the article about novartis presents new 48 week results from phase iii apply pnh trial showing sustained efficacy and long term safety of fabhalta iptacopan in adults with paroxysmal nocturnal hemoglobinuria pnh was published today ( Monday 11/12/2023 - 03:48 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH) )

Also on site :

• Enbridge aims to help North America win from the AI boom and the Iran war as the FedEx of energy delivery
• Quote of the Day: Organizational Psychologist Adam Grant on Rethinking Self-Doubt and Building Confidence
• Stellantis N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - STLA